Startups
Auristone
Auristone develops epigenomic profiling tests, predictive models and research services for precision oncology, with a focus on Asian populations and diseases. Its EPI-CALL test combines epigenomic and genomic information to provide clinically actionable insights about cancer and treatment response. Its Signomax research service supplies RNA sequencing, chromatin immunoprecipitation sequencing and bioinformatics analysis; the company’s histone-modification technology and epigenomic database also support biomarker and drug discovery.
Founded 2021